A recent study suggested that LPS/TLR4-induced signaling cascades leads to inducible nitric oxide synthase (iNOS) induction, and inhibition of iNOS might be as a novel effective target therapy against triple-negative breast cancer [32]. This evidence concerns the gene TLR4 and triple-negative breast carcinoma.